Early-stage VC and venture studio backing food, climate, and biotech founders
FoodLabs operates as both an early-stage investor and an in-house venture studio, backing founders across food systems, climate, and synthetic biology. The tech stack reveals a biotech-inflected operation: Python, R, Snakemake, and Nextflow sit alongside workflow automation (n8n, Zapier, Make), signaling active involvement in portfolio-company technical architecture and data pipelines. Active hiring across product, marketing, and commercial roles, with notable leadership positions (Product Head, Head of Venture Studio, Sales Lead), suggests the studio is scaling internal operations to support more portfolio companies and establish a repeatable go-to-market engine.
Notable leadership hires: Product Head, Head of Product, Head of Venture Studio, Sales Lead, Head of Commercial
FoodLabs is an early-stage VC investor and venture studio founded in 2016 and based in Berlin. The firm has built and invested in more than 80 early-stage companies, focusing on solutions spanning consumer food, supply-chain infrastructure, health, agriculture, livestock, climate, and synthetic biology. Beyond traditional capital deployment, the studio operates an internal function to identify opportunities and co-found ventures alongside scientific and entrepreneurial founders. The firm supports companies globally while maintaining an engineering-forward approach, as evidenced by active projects in genomic data pipelines, enzyme design, and variant discovery infrastructure. Current pain points include scaling manufacturing, establishing repeatable sales processes, and reducing churn across the portfolio.
Python, R, Bash, Snakemake, Nextflow, GitHub, TikTok, Meta, n8n, Make, Zapier, CAD, and Shopify. The biotech-focused languages (Python, R, Snakemake, Nextflow) reflect heavy involvement in genomic and phenotypic data pipelines.
Portfolio support (MVP building, go-to-market loops, onboarding flows), studio asset development, and deep technical work on generative enzyme design, genomic pipelines, and variant discovery infrastructure for portfolio companies.
Other companies in the same industry, closest in size